摘要
背景:在神经退行性疾病中GSK3ββ与病理功能相关。这种激酶参与微管相关tau蛋白过度磷酸化,导致神经纤维缠结的聚集和形成。已清楚地表明,GSK3β是在翻译后水平调节:在tyr216激活激酶磷酸化,在Ser9磷酸化抑制其活性是必不可少的。 目的:目前,有许多的当代研究表明βGSK3可能在基因水平调控具有可能性。以往的数据显示GSK3βmRNA表达低甲基化的条件,指出了表观遗传机制βGSK3基因调控的存在。通过亚硫酸氢盐修饰人类GSK3β启动子分析,在神经母细胞瘤细胞和死后额叶皮层从AD患者(AD患者在Braak阶段I-II和阶段V-VI),允许我们来表征一个CpG岛的甲基化模式在人类GSK3β5’侧翼。 结果:分析证明整体低甲基化CpG和非CpG胞嘧啶残基在细胞和人脑(AD患者和对照组)。我们发现,βmRNA表达,GSK3只有在患者最初的AD中,在蛋白水平没有影响。另一方面,我们意外地发现与对照组相比,从AD患者皮质激活GSK3β减少在Braak阶段I-II级,而观察AD患者的阶段是相当大的增加。 结论:这些结果指出,GSK3β多动、NFT可在疾病的早期阶段来然后在关闭的最后阶段产生某种功能。
关键词: GSK3β、磷酸化、晚发型阿尔茨海默病,DNA甲基化,GSK3β基因,老年痴呆症患者,tau。
Current Alzheimer Research
Title:GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients
Volume: 14 Issue: 7
关键词: GSK3β、磷酸化、晚发型阿尔茨海默病,DNA甲基化,GSK3β基因,老年痴呆症患者,tau。
摘要: Background: The GSK3β has been associated to pathological functions in neurodegenerative diseases. This kinase is involved in hyperphosphorylation of microtubule-associated tau protein, leading to aggregation andformation of NFTs. It has clearly been shown that GSK3β is regulated at posttranslational level: phosphorylation at Tyr216 activates kinase, while phosphorylation at Ser9 is essential to inhibit its activity.
Objectives: At present, there are contradictory findings about the possibility that GSK3β may be regulated at gene level. Previous data showed overexpression of GSK3β mRNA in hypomethylating conditions, pointing out to the existence of epigenetic mechanisms responsible for GSK3β gene regulation. Analysis of human GSK3β promoter through bisulphite modification, both in neuroblastoma cells and in postmortem frontal cortex from AD patients (AD patients both at Braak stages I-II and at stages V-VI) , allowed us to characterize the methylation pattern of a putative CpG islands in human GSK3β 5’- flanking region. Results: The analysis evidenced overall hypomethylation of CpG and non-CpG cytosine residues both in cells and in human brain (AD patients and control subjects). We found that GSK3β mRNA was overexpressed only in patients with initial AD, with no effect on the levels of the protein. On the other hand, we unexpectedly observed the decrease of the inactive GSK3β in cortex from AD patients at Braak stages I-II, whereas considerable increase was observed in AD patients at stages V-VI compared to the control subjects. Conclusions: These results point out that GSK3β hyperactivity, and then NFTs formation, could come into function at an early stage of the disease and then turn off at the last stages.Export Options
About this article
Cite this article as:
GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients, Current Alzheimer Research 2017; 14 (7) . https://dx.doi.org/10.2174/1567205014666170203153325
DOI https://dx.doi.org/10.2174/1567205014666170203153325 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Inhibition of β-Amyloid Aggregation by Albiflorin, Aloeemodin and Neohesperidin and their Neuroprotective Effect on Primary Hippocampal Cells Against β-Amyloid Induced Toxicity
Current Alzheimer Research Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews Opioid Receptor Interacting Proteins and the Control of Opioid Signaling
Current Pharmaceutical Design Chemoprotective and Carcinogenic Effects of tert-Butylhydroquinone and Its Metabolites
Current Drug Metabolism Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Reversible and Irreversible Aggregation of Proteins from the FET Family: Influence of Repeats in Protein Chain on Its Aggregation Capacity
Current Protein & Peptide Science Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Determination of Human Serum α1-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Current Medicinal Chemistry The Doublecortin Gene Family and Disorders of Neuronal Structure
Central Nervous System Agents in Medicinal Chemistry Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry Patents in Cancer Stem Cells
Recent Patents on Biomarkers Liposome-linear polyethyleneimine-DNA Nanocomplexes for Gene Delivery: Preparation, Characterization and In Vitro Transfection Activity
Current Nanoscience